Discovery of novel phosphodiesterase-1 inhibitors for curing vascular dementia: Suppression of neuroinflammation by blocking NF-κB transcription regulation and activating cAMP/CREB axis.
10.1016/j.apsb.2022.09.023
- Author:
Qian ZHOU
1
;
Meiling LE
1
;
Yiyi YANG
1
;
Wenjuan WANG
2
;
Yuqi HUANG
1
;
Quan WANG
1
;
Yijing TIAN
1
;
Meiyan JIANG
1
;
Yong RAO
2
;
Hai-Bin LUO
1
;
Yinuo WU
1
Author Information
1. School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou 510006, China.
2. Key Laboratory of Tropical Biological Resources of Ministry of Education and One Health Institute, School of Pharmaceutical Sciences, Hainan University, Haikou 570228, China.
- Publication Type:Journal Article
- Keywords:
Neuroinflammation;
Phosphodiesterase 1 (PDE1);
Structural-based drug design;
Vascular dementia;
cAMP/CREB axis
- From:
Acta Pharmaceutica Sinica B
2023;13(3):1180-1191
- CountryChina
- Language:English
-
Abstract:
Vascular dementia (VaD) is the second commonest type of dementia which lacks of efficient treatments currently. Neuroinflammation as a prominent pathological feature of VaD, is highly involved in the development of VaD. In order to verify the therapeutic potential of PDE1 inhibitors against VaD, the anti-neuroinflammation, memory and cognitive improvement were evaluated in vitro and in vivo by a potent and selective PDE1 inhibitor 4a. Also, the mechanism of 4a in ameliorating neuroinflammation and VaD was systematically explored. Furthermore, to optimize the drug-like properties of 4a, especially for metabolic stability, 15 derivatives were designed and synthesized. As a result, candidate 5f, with a potent IC50 value of 4.5 nmol/L against PDE1C, high selectivity over PDEs, and remarkable metabolic stability, efficiently ameliorated neuron degeneration, cognition and memory impairment in VaD mice model by suppressing NF-κB transcription regulation and activating cAMP/CREB axis. These results further identified PDE1 inhibition could serve as a new therapeutic strategy for treatment of VaD.
